References
- Ebrahim S, Daponte A, Guidozzi F. The impact of free antenatal care on perinatal mortality. Int J Gynaecol Obstet. 2000; 71(3): 205-207.
- Alfirevic Z, Neilson JP. Antenatal screening for Down's syndrome. Br Med J. 2004; 329(7470): 811-812.
- Spencer K. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum βhCG and PAPP-A. Br J Obstet Gynaecol. 2001; 108: 1043-1046.
- Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med. 1999; 341(7): 461-467.
- Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen. 2003; 10(2): 56-104. (Erratum in: J Med Screen. 2006; 13(1): 51-52.)
- Stojilkovic-Mikic T, Rodeck CH. Screening for chromosomal anomalies: first or second trimester, biochemical or ultrasound? Ann Acad Med Singapore. 2003; 32(4): 583-589.
- Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med. 1998; 338(14): 955-961.
- Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Br J Obstet Gynaecol. 1996; 103(5): 407-412.
- Snijders RJM, Farrias M, Kaisenberg C, Nicolaides KH. Fetal abnormalities. In: Sniijders RJM, Nicolaides KH, Eds. Ultrasound Markers for Fetal Chromosomal Defects. New York: Parthenon, 1996: 1-63.
- Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Gilstrap L, Wenstrom KD, Eds. Prenatal diagnosis and fetal therapy. Williams Obstetrics. New York: McGraw-Hill, 2005: 313-340.
- Wellesley D, Boyle T, Barber J, Howe DT. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region. Br Med J. 2002; 325(7354): 15-17.
- Lončar D, Varjačić M, Novaković T, Milovanović D, Janković S. Correlation between serum biochemical markers and early amniocentesis in diagnosis of congenital fetal anomalies. Bosnian J Basic Med Sci. 2010; 10(1): 9-14.
- Hallahan T, Krantz D, Orlandi F, Rossi C, Curcio P, Macri S, Larsen J, Buchanan P, Macri J. First trimester biochemical screening for Down syndrome: free β-hCG versus intact hCG. Prenat Diagn. 2000; 20(10): 785-789.
- Brigatti KW, Malone FD. First trimester screening for aneuploidy. Obstet Gynecol Clin North Am. 2004; 31(1): 1-20.
- Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. 2004; 191(1): 45-67.
- Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 1999; 13(4): 231-237.
- Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol. 2000; 96(2): 207-213.
- Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol. 2000; 107(10): 1271-1275.